MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

ANTHEM-HFrEF

  • Home
  • ANTHEM-HFrEF
Vagal Nerve Stimulation in HFrEF Was Safe but Did Not Improve the Primary Composite Outcome in the ANTHEM-HFrEF Trial
Posted inCardiology news

Vagal Nerve Stimulation in HFrEF Was Safe but Did Not Improve the Primary Composite Outcome in the ANTHEM-HFrEF Trial

Posted by By MedXY 05/23/2026
In ANTHEM-HFrEF, vagal nerve stimulation in symptomatic HFrEF was feasible and safe, but the underpowered trial did not meet its primary efficacy endpoint after premature sponsor-driven termination.
Read More
  • Cascade Genetic Screening in Hereditary Transthyretin Amyloidosis: Unlocking Earlier Diagnosis and Improved Outcomes
  • Site-Specific Apo AI Glycation Impairs HDL Function and Promotes Atherosclerosis in Diabetes
  • Association of Adherence to Various Dietary Patterns With Mortality Among Survivors of Myocardial Infarction: An Evidence-Based Review
  • Bridging Social Determinants of Health and Multidimensional Frailty Among Older Adults: A Domain-Specific Latent Class and Network Analysis
  • How Respiratory Mechanics Shapes Ventilator Settings and Outcomes in Acute Brain Injury Patients
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis prostate cancer public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top